> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pediatric Oncology Drugs Advisory Committee Meeting 6/20
- URL: https://www.fdaweb.com/pediatric-oncology-drugs-advisory-committee-meeting-6-20/
- Published: 2018-05-15T12:00:00.000Z
- Updated: 2026-09-15T00:05:16.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141435

*Federal Register* notice: FDA has announced a Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee meeting 6/20 to review and discuss a list of molecular targets for which evidence or biologic rationale exist to determine their potential relevance to the growth or progression of one or more pediatric cancers and a list of those targets deemed unlikely to be associated with the growth or progression of pediatric tumors. The lists are expected to fulfill a statutory obligation in the FDA Reauthorization Act (FDARA) and provide some guidance to industry in planning for initial pediatric study plan submissions for new drug/biologic products. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-05-15/pdf/2018-10337.pdf?ref=fdaweb.com).